文献速递食管与纵隔外科

T2N0食管癌诱导治疗使用模式分析

Patterns of Use of Induction Therapy for T2N0 Esophageal Cancer.
PubMed 文献 · Ann Thorac Surg · 2020-07-15

基于美国国家癌症数据库2004-2015年2540例cT2N0M0食管癌食管切除术患者的回顾性队列分析,46%接受 upfront 手术,53%接受诱导治疗。诱导治疗与生存获益无关,但其使用与诊断年份较晚、肿瘤较大和分级较高独立相关。

要点

  • cT2N0M0食管癌中诱导治疗使用率53%,但未显示生存获益。
  • 诱导治疗更多用于年轻、男性、无合并症、有私人保险及非学术中心患者。
  • upfront手术更多用于高龄、有合并症、无保险及最高手术量中心患者。

核心结论

  • cT2N0M0食管癌中诱导治疗的使用与多种患者、治疗中心和肿瘤因素相关,但诱导化疗与无诱导治疗相比未显示生存获益。

研究设计与样本

  • 回顾性队列分析,查询美国国家癌症数据库2004-2015年接受食管切除术的cT2N0M0食管癌患者,共2540例符合标准。

主要发现

  • 2540例中1177例(46%)接受 upfront 食管切除术,1363例(53%)接受诱导治疗。
  • 诱导治疗组更可能为年轻、男性、无合并症、有私人保险及在非学术中心治疗,且较少在最高手术量中心治疗。
  • 多变量回归中,与接受诱导治疗独立相关的因素包括诊断年份较晚、肿瘤尺寸增大和肿瘤分级增高。
  • 与 upfront 食管切除术相关的因素包括年龄增长、合并症、无保险、地理位置和最高手术量中心。
  • 诱导化疗与无诱导治疗相比未显示生存获益。

临床怎么用

  • 对于cT2N0M0食管癌,诱导治疗的选择需考虑患者年龄、合并症、保险状态及治疗中心特征,但不应期望明确的生存获益。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Induction therapy for patients with cT2N0M0 esophageal cancer is controversial. We performed a retrospective cohort analysis of the National Cancer Database to examine the patterns of use of induction therapy for this population. METHODS: The National Cancer Database was queried for patients with cT2N0M0 esophageal cancer who underwent esophagectomy (2004-2015). Patients were stratified by upfront surgery or induction therapy. Overall survival was analyzed and a multivariable logistic regression performed to identify factors associated with receipt of induction therapy. RESULTS: Overall 2540 patients met study criteria: 1177 (46%) received upfront esophagectomy and 1363 (53%) received induction therapy. Patients receiving induction therapy were more likely to be younger, male, without comorbidities, privately insured, and treated at a nonacademic center. These patients were also less likely to be treated in highest volume surgery centers. In multivariable regression, factors independently associated with receipt of induction therapy included later year of diagnosis, increasing tumor size, and increasing tumor grade. Factors associated with upfront esophagectomy included advancing age, comorbidities, lack of insurance, geographic location, and highest volume centers. The receipt of induction chemotherapy was not associated with a survival benefit compared with no induction therapy. CONCLUSIONS: Several patient-, treatment center-, and tumor-related factors are associated with receipt of induction therapy for cT2N0M0 esophageal cancer, although induction therapy is not associated with a survival benefit. Further inquiry into these differences and the potential benefit or lack thereof of induction therapy should be conducted to provide more equitable and appropriate care for patients with esophageal cancer.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Rhodin KE, Raman V, Jawitz OK, et al. Patterns of Use of Induction Therapy for T2N0 Esophageal Cancer. Ann Thorac Surg. 2020. PMID: 32681837. doi:10.1016/j.athoracsur.2020.05.089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。